Clinical Trials · NCT00210457
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ipsen
- Enrollment
- 63
- Start date
- Sep 2000
- Locations
- 17 sites, France, Switzerland
- Primary endpoint
- Percentage of patients having a normal (age-adjusted) serum insulin-like growth factor 1 (IGF-1) level at end point (Week 48)